Potentiation of Antineoplastic Agents Using Sigma 2 Ligands
Description of Invention:
The inventors have developed a therapeutic method of treating cancer through the administration of a sigma-2 receptor ligand, such as CB-184, in combination with the anti-neoplastic drugs, doxorubicin or actinomycin D. The novel combination produces marked tumor cell death at concentrations that produce little or no cytotoxicity when cells are exposed to the drugs alone. The protocol may be effective in treating tumors that are resistant to antineoplastics alone as a result of mutations of the p53 tumor suppressor gene.
Inventors:
Keith W. Crawford and Wayne D. Bowen (NIDDK)
Patent Status:
DHHS Reference No. E-165-1999/0 --
U.S. Provisional Application No. 60/203,200 filed 11 May 2000
PCT Application No. PCT/US01/40688 filed 08 May 2001, which published as WO 01/85153 on 15 Nov 2001
U.S. Patent Application No. 10/275,830 filed 09 May 2003
U.S. Patent Application No. 11/497,945 filed 01 Aug 2006
Portfolios: Cancer
Cancer -Therapeutics-Biological Response Modifiers Cancer -Therapeutics
For Additional Information Please Contact: Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4633
Email: wongje@mail.nih.gov
Fax: (301)402-0220
